Discovery of triazolone derivatives as novel, potent stearoyl-CoA desaturase-1 (SCD1) inhibitors.

[1]  N. Dales,et al.  Opportunities and challenges in developing stearoyl-coenzyme A desaturase-1 inhibitors as novel therapeutics for human disease. , 2014, Journal of medicinal chemistry.

[2]  D. Powell.  An overview of patented small molecule stearoyl coenzyme-A desaturase inhibitors (2009 – 2013) , 2014, Expert opinion on therapeutic patents.

[3]  D. McLaren,et al.  Systematic evaluation of amide bioisosteres leading to the discovery of novel and potent thiazolylimidazolidinone inhibitors of SCD1 for the treatment of metabolic diseases. , 2014, Bioorganic & medicinal chemistry letters.

[4]  D. McLaren,et al.  Discovery of thiazolylpyridinone SCD1 inhibitors with preferential liver distribution and reduced mechanism-based adverse effects. , 2014, Bioorganic & medicinal chemistry letters.

[5]  J. Lenhard,et al.  4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: part 2. Pyridazine-based analogs. , 2013, Bioorganic & medicinal chemistry letters.

[6]  A. Winiski,et al.  Pharmacological inhibition of stearoyl CoA desaturase in the skin induces atrophy of the sebaceous glands. , 2013, The Journal of investigative dermatology.

[7]  J. Copland,et al.  Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma , 2013, Clinical Cancer Research.

[8]  D. McLaren,et al.  Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome. , 2013, Journal of medicinal chemistry.

[9]  S. Culine,et al.  Abrogation of De novo Lipogenesis by Stearoyl-CoA Desaturase 1 Inhibition Interferes with Oncogenic Signaling and Blocks Prostate Cancer Progression in Mice , 2010, Molecular Cancer Therapeutics.

[10]  S. Summers,et al.  Lipid oversupply, selective insulin resistance, and lipotoxicity: molecular mechanisms. , 2010, Biochimica et biophysica acta.

[11]  Gang Liu.  Recent advances in stearoyl-CoA desaturase 1 inhibitors for dyslipidemia and obesity. , 2010, Current topics in medicinal chemistry.

[12]  Zhihua Jiang,et al.  Significant associations of stearoyl-CoA desaturase (SCD1) gene with fat deposition and composition in skeletal muscle , 2008, International journal of biological sciences.

[13]  M. Miyazaki,et al.  Loss of stearoyl-CoA desaturase 1 inhibits fatty acid oxidation and increases glucose utilization in the heart. , 2008, American journal of physiology. Endocrinology and metabolism.

[14]  E. Ingelsson,et al.  Polymorphisms in the SCD1 Gene: Associations With Body Fat Distribution and Insulin Sensitivity , 2007, Obesity.

[15]  B. Monia,et al.  Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance. , 2006, The Journal of clinical investigation.

[16]  D. Moller,et al.  Modulation of fatty acid metabolism as a potential approach to the treatment of obesity and the metabolic syndrome , 2006, Endocrine.

[17]  E. Hoffman,et al.  Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. , 2005, Cell metabolism.

[18]  R. A. Igal,et al.  Stearoyl-CoA Desaturase Is Involved in the Control of Proliferation, Anchorage-independent Growth, and Survival in Human Transformed Cells* , 2005, Journal of Biological Chemistry.

[19]  R. Schmidt,et al.  Characterization of HSCD5, a novel human stearoyl-CoA desaturase unique to primates. , 2005, Biochemical and biophysical research communications.

[20]  Margaret S. Wu,et al.  Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. , 2005, The Journal of clinical investigation.

[21]  Manabu T. Nakamura,et al.  STRUCTURE, FUNCTION, AND DIETARY REGULATION OF Δ6, Δ5, AND Δ9 DESATURASES , 2004 .

[22]  J. Friedman,et al.  Identification and Characterization of Murine SCD4, a Novel Heart-specific Stearoyl-CoA Desaturase Isoform Regulated by Leptin and Dietary Factors* , 2003, Journal of Biological Chemistry.

[23]  B. Yandell,et al.  Loss of stearoyl–CoA desaturase-1 function protects mice against adiposity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Miyazaki,et al.  Targeted disruption of stearoyl-CoA desaturase1 gene in mice causes atrophy of sebaceous and meibomian glands and depletion of wax esters in the eyelid. , 2001, The Journal of nutrition.

[25]  J. Sundberg,et al.  Scd3--a novel gene of the stearoyl-CoA desaturase family with restricted expression in skin. , 2001, Genomics.

[26]  J. Sundberg,et al.  Asebia-2J (Scd1(ab2J)): a new allele and a model for scarring alopecia. , 2000, The American journal of pathology.

[27]  L. Zhang,et al.  Human stearoyl-CoA desaturase: alternative transcripts generated from a single gene by usage of tandem polyadenylation sites. , 1999, The Biochemical journal.

[28]  P. Needleman,et al.  Identification and Characterization of a Novel Δ6/Δ5 Fatty Acid Desaturase Inhibitor As a Potential Anti-Inflammatory Agent , 1998 .

[29]  K. Kaestner,et al.  Differentiation-induced gene expression in 3T3-L1 preadipocytes. A second differentially expressed gene encoding stearoyl-CoA desaturase. , 1989, The Journal of biological chemistry.

[30]  K. Kaestner,et al.  Differentiation-induced gene expression in 3T3-L1 preadipocytes. Characterization of a differentially expressed gene encoding stearoyl-CoA desaturase. , 1988, The Journal of biological chemistry.

[31]  B. Talamo,et al.  A new assay for fatty acid desaturation. , 1969, Analytical biochemistry.

[32]  Funda Meric-Bernstam,et al.  High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients , 2012, Breast Cancer Research and Treatment.

[33]  J. Ntambi,et al.  The regulation of stearoyl-CoA desaturase (SCD). , 1995, Progress in lipid research.